skip to Main Content
Next Frontier Biosciences Expands Ranks with New Regional Sales Manager

 

PRESS RELEASE

Growing biotech company strengthens sales team, prepares for product launch

DENVER (October 11, 2017) – As Next Frontier Biosciences prepares to launch its Verra Wellness line of purified cannabinoid products in November, the Colorado-based biotech company has enhanced its experienced sales lineup with the addition of a new Regional Sales Manager, Colin Osborne.

In preparation for the product launch, Osborne plays a key role in generating a new customer base, forging and fostering strong relationships and educating clients on which products best suit their needs. In addition, he develops and implements an optimal sales strategy and product promotion while ensuring brand integrity.

Prior to joining Next Frontier Biosciences, Osborne worked in sales for nine years, notably serving as Sales Manager at Weaver Fundraising, LLC. He also served as Enterprise Software Sales Executive at BigMachines, Inc. and Executive Sales Representative at CBLPath, Inc. He later discovered a passion for the cannabis industry as Account Representative and Project Manager at ALl Packaging Company in Aurora, Colorado, and most recently in his role as Retail Associate at The Green Solution in Denver. A former Marine Officer, Osborne earned his bachelor’s degree from Gettysburg College and his master’s degree from Villanova University.

“Colin brings a strong and unique combination of leadership, sales and cannabis industry experience to Next Frontier Biosciences, making him well equipped to lead our regional sales team in introducing Verra Wellness to the market,” said Beth Dresser, Senior Director of Sales and Marketing at Next Frontier Biosciences. “We welcome his insights and know that our clients and staff will benefit from his guidance as we launch the brand in Colorado and establish ourselves as a global cannabis-infused products leader in other markets.”

For more information or to schedule an interview with Next Frontier Biosciences, please contact Shawna McGregor at 917-971-7852 or [email protected].

About Next Frontier Biosciences: Next Frontier Biosciences is a Colorado-based biotech company focused on developing and commercializing best-in-class purified cannabinoid products that are scientifically formulated for improved delivery. Comprised of an experienced group of biotechnology executives and research scientists, Next Frontier Biosciences is pioneering the development of purified cannabinoid products that provide accurate dosing, improved bioavailability and optimized cannabinoid profiles for fast acting and consistent results. Next Frontier Biosciences’ goal is to leverage its proprietary formulations and premium brand strategy to become a global leader in the market for next-generation cannabis infused products.

The company is led by a talented group of biotech executives and research scientists that help set it apart from the competition. Marc Graboyes, J.D., Next Frontier Biosciences’ co-founder and Chief Executive Officer, is responsible for leading the development and execution of the company’s long-term strategy as well as the day-to-day management of the company’s affairs. Mr. Graboyes has over two decades of experience working with emerging growth companies and the investors that support them, including eight years as Senior Vice President and General Counsel of Allos Therapeutics, Inc., a biotech company that he helped take public and sell for nearly $200 million. Prior to that, he was a corporate attorney with several large national law firms, including nearly five years with Cooley LLP. Mr. Graboyes is a seasoned business executive and attorney with deep experience in the areas of strategic planning, corporate finance, corporate development, technology transactions, and mergers and acquisitions, among other areas.

Dr. Paul Johnson, Ph.D., Next Frontier Biosciences’ co-founder and Chief Scientific Officer, has over four decades of experience in the pharmaceutical industry. He is an expert in intranasal drug development and delivery systems, and authored or invented over 100 patents and scientific publications. Dr. Johnson has experience in drug delivery and development, molecular diagnostics, cell biology, molecular biology and biochemistry/biophysics. In addition, he has led research and development activities for FDA approved drugs including Betaseron, the first-ever FDA approved drug to treat multiple sclerosis. He received a B.S. in Molecular Biology from the State University of New York, a Ph.D. in Biochemistry from the Roswell Park Cancer Institute, and conducted his postdoctoral training in biophysics and biology under an American Cancer Society fellowship at the California Institute of Technology.

Dr. Dorothy “Dot” Colagiovanni, Ph.D., Next Frontier Biosciences’ Vice President of Pharmaceutical Development, is responsible for the day-to-day management of the company’s research and development activities as well as supporting the commercialization of the company’s products. She has over two decades of pharmaceutical development experience with an emphasis on project management, pharmacology and toxicology. Prior to joining the company, Dr. Colagiovanni held scientific leadership roles with Nivalis Therapeutics and Replidyne, and she also held research positions with OSI Pharma, Gilead Sciences and Nexstar. Dr. Colagiovanni has a broad range of pharmaceutical development experience, starting with early drug discovery and clinical trials through regulatory approval and commercial launch. She completed her Ph.D. at University of Colorado Health Sciences Center in Molecular Toxicology and a postdoctoral fellowship at Amgen in hematotoxicology.

For more information, visit http://nextfrontierbio.com/. Follow us on Facebook, Twitter, Instagram and LinkedIn.

This Post Has 0 Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Stories

Colorado’s cannabis industry makes modest gains in minority ownership

Almost 17% of regulated marijuana business owners in Colorado identify as minorities, according to new data by the Colorado Marijuana Enforcement Division, but one Black entrepreneur contests that there’s much more work to be done. “Cannabis ownership in Colorado is still a pipe dream for people of color,” said Wanda James, founder and CEO of…

Industry group recommends new medical cannabis rules for Maine

A group of medical marijuana providers, customers and other interested parties made recommendations to a legislative committee Monday for new rules that it says would protect consumers without causing undue harm to Maine’s medical cannabis industry. A bill approved by the Maine Legislature in 2021 overhauled the medical marijuana rulemaking process and halted a set of controversial…

New York regulators expand access to medical marijuana program

Marijuana will be easier to prescribe and use for medical purposes in New York under recently finalized regulatory changes. The state Office of Cannabis Management said the new certification and registration system officially announced Monday eliminates the list of qualifying conditions — a patient can now be certified for medical marijuana use for any condition…

Arizona recreational marijuana sales worth over half a million dollars in 2021

New data from the Arizona Dept. of Revenue shows that one year after recreational marijuana use became legal in the state, its generated over $44 million in tax revenue. Combined with medical marijuana sales, total sales of marijuana topped $1.2 billion in 2021. After steady growth January and February of last year, recreational total sales…

More Categories

Back To Top
×Close search
Search